NCT04500301View on ClinicalTrials.gov

Pharmacogenomic Testing to Personalize Supportive Oncology

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 2, 2020

Primary Completion Date

December 13, 2023

Study Completion Date

December 13, 2023

Conditions
CancerDepressionPain
Interventions
OTHER

Preemptive Pharmacogenomic Testing

The use of a pharmacogenomic (PGx) testing to help manage drugs prescribed to subjects for pain and depression.

Trial Locations (1)

28204

Levine Cancer Institute, Charlotte

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER

NCT04500301 - Pharmacogenomic Testing to Personalize Supportive Oncology | Biotech Hunter | Biotech Hunter